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6/j.bExtracorporeal photopheresis (ECP) is emerging as a therapy for graft-versus-host-disease (GVHD), but the
full mechanism of action and the impact on immunity have not been fully established. After murine minor his-
tocompatibility antigen–mismatched bonemarrow (BM) transplantation (allo-BMT), coinfusionof ECP-treated
splenocyteswith T cell–replete BM attenuatedGVHD irrespective of the donor strain of the ECP-treated sple-
nocytes, and was associated with increased numbers of regulatory T cells. Coculture of myeloid dendritic cells
(DCs) with ECP-treated splenocytes resulted in increased interleukin (IL)-10 production after submaximal
stimulation with lipopolysaccharide. Furthermore, male myeloid DCs exposed to ECP-treated splenocytes
were less potent at inducing CD81 HY responses when used as a vaccine in vivo. The efficacy of ECP-
treated splenocyteswas enhancedwhen administered just before delayed donor lymphocyte infusion following
T cell–depleted allo-BMT, allowing for the administration of sufficient numbers of T cells to respond tomyeloid
DCvaccination in the absence of a thymus. Finally, the therapeutic effect of ECP-treated splenocytes was lost in
recipients of IL-10–deficient BM.We demonstrate that ECP-treated splenocytes attenuateGVHD irrespective
of the source of ECP-treated cells via a mechanism that likely involves modulation of DCs and requires IL-10
produced by BM-derived cells. Importantly, the attenuation of GVHDby ECP-treated splenocytes permits do-
nor lymphocyte infusion–dependent responses to DC vaccines after allo-BMT.
Biol Blood Marrow Transplant 17: 790-799 (2011) Published by Elsevier Inc. on behalf of American Society for Blood and
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bmt.2010.12.712morbidity, and it remains the leading cause of nonre-
lapse mortality [1]. Although matching the donor and
recipient to major histocompatibility complex (MHC)
antigens reduces the chance of developing GVHD,
the recognition of host minor histocompatibility anti-
gens (mHAs) by donor T cells can still lead to clinically
significant GVHD [2]. Steroids, the first-line therapy
for treating GVHD, fail in 50% of patients [1]. In addi-
tion, steroids are globally immunosuppressive, increas-
ing the risk of relapse and infections. Thus, strategies to
mitigateGVHDwhile preserving immune functionwill
be important in improving outcomes after allo-BMT.
Extracorporeal photopheresis (ECP) is a clinical
procedure that involves exposure of peripheral blood
leukocytes isolated by apheresis to a photosensitizer,
such as 8-methoxypsoralen (8-MOP) and ultraviolet A
(UVA) radiation, followed by reinfusion into the
patient. Cells treated in this manner have been shown
in vitro to sustain damage to the cell membrane,
with formation of monoadducts and cross-linking of
Biol Blood Marrow Transplant 17:790-799, 2011 791Impact of ECP on GVHD and DC VaccinesDNA [3,4] as well as activation of caspases, leading to
protracted apoptosis [5] and immune modulation after
reinfusion. ECP has demonstrated efficacy in treating
both acute and chronic GVHD, allowing a reduction
in or cessation of immunosuppressive medications
[6-9]. Although the literature is conflicting, it appears
that the likelihood of response is dependent on the
organ(s) involved, with the skin one of the most
responsive sites [10].Theonepublishedprospective ran-
domized study of ECP in chronic GVHD involving the
skin in adults reported a modest, but statistically signifi-
cant, reduction in steroid dose in theECP treatment arm
[11]. A number of prospective trials assessing the efficacy
of ECP as therapy for acute or chronic GVHD are
planned or ongoing. Although the definitivemechanism
of ECP in immune modulation has not yet been eluci-
dated, a number of immunological alterations are in-
ducedbyECP, including expansion of regulatoryT cells
(Tregs) [6-9] and modulation of cytokine production
and maturation of dendritic cells (DCs) [12-14]. Thus,
insights into the complex immunological effects
induced by ECP will be critical to optimizing ECP as
a therapeutic approach for GVHD.
Murinemodels have begun to shed light on the im-
munologica effect of ECP. In recipients of ECP-
treated cells, T cell responses to haptens are inhibited
in an antigen-specific manner [15,16], and this
tolerance can be transferred to na€ıve animals [9,15]
with preferential trafficking of ECP-treated cells to
the spleen [9,17]. However, despite the availability of
rodent and primate animal models for examining the
mechanism of ECP in treating autoimmune diseases
and preventing cardiac allograft rejection over the
last 20 years [17,18], mechanistic studies in allo-
BMT models have been limited [19,20]. Initial
observations showed that GVHD mediated by both
MHC-mismatched and mHA-mismatched BM could
be minimized by ECP with some evidence of main-
tained graft-versus-leukemia effects [20]. More recent
studies have attributed the mechanism of ECP to
the induction of Tregs [6,9]. Finally, preclinical
autoimmune and solid-organ allograft models of
ECP [8], as well as models of ultraviolet B exposure
[21], have described selective deletion or suppression
of pathogenic T cells [22]. Thus, ECP may offer the
advantage of working in an antigen-specific manner,
avoiding some of the global immunosuppression
associated with prolonged steroid use. Emerging evi-
dence suggests that apoptotic cells can impact immune
responses through modulation of DC function
[12,14,23,24]. Given that ECP involves the infusion
of cells undergoing apoptosis, we hypothesized that
modulation of DCs is the central mechanism by
which ECP diminishes alloreactivity, and that this
may result in preserved immune responses to
nonalloantigens targeted by vaccination.MATERIALS AND METHODS
Mice
C57/BL6 (B6), B6 IL-10-/-, C3H.SW  B6 (F1),
C3H.SW, and BALB.B mice (all H-2b) were purchased
from Jackson Laboratories (Bar Harbor, ME). All of
these mice are MHC antigen-matched and mHA-
mismatched at multiple antigens [25]. C3H.HeNCr
(H-2k) mice were purchased from the National Cancer
Institute Animal Production Program (Frederick, MD).
Mice were age-matched and used between 6 and 12
weeks of age.Where indicated, thymectomizedmice un-
derwent vacuum suction removal of the thymus accord-
ing to a standard protocol. These animals were housed in
pathogen-free conditions throughout the study. The
National Institutes of Health’s Animal Care and Use
Committee at the approved all protocols.BMTand Donor Lymphocyte Infusion
BM was harvested, and where indicated, T cell–
depleted as described previously [26]. Lethally irradiated
(10Gy)C3H.SWorF1 recipientmice received an i.v. in-
jection through the tail vein with 10 106T cell–replete
(TCR; enriched with 5  106 lymph node cells) or 4 
106 T cell-depleted (TCD) B6 BM cells in serum-free
RPMI media (Invitrogen, Carlsbad, CA). The engraft-
ment was confirmed by flow cytometric analysis of
spleens of F1 recipients (CD45.11/CD45.21) who un-
derwent transplantation with TCD B6 (CD45.1-/
CD45.21) BM. Donor lymphocyte infusion (DLI), ob-
tained from single-cell suspensions of pooled inguinal
and axillary lymph nodes, was administered on days
114 and 128 post-BMT where indicated. Cells were
washed and counted, and the entire lymph node suspen-
sion was resuspended in serum-free RPMI medium for
i.v. injection through the tail vein. No deletions of cell
subsets were performed.
Recipients were weighed individually twice every 7
days, and the mean weight of each treatment group
was calculated at each time point and compared with
the day 0 weight. Evaluation of survival and clinical
monitoring of GVHD, including observation for skin
changes (ruffling or hair loss), diarrhea, and hunched
posture, was done daily, although in this MHC-
matched, mHA-mismatched BMT model, GVHD was
best measured by weight loss and diminished splenic B
cells counts, as shown previously [26]. ‘‘Attenuation’’
of GVHD was defined as weight loss that was signifi-
cantly less than that seen in GVHD controls. Immune
reconstitution by flow cytometry is detailed in the
Supplemental Methods. Examination for moribund
mice was performed by a veterinarian and veterinary
technicianswhowereblinded to theexperimental design
and groups, and who assessed the mice daily in accor-
dance with approved institutional protocols.
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ECP treatment involved harvesting spleens from
appropriate donors and resuspending at 10  106
cells/mL.Where noted, depletion of B cells andT cells
was done by magnetic cell selection with anti-B220 or
anti-CD3 microbeads (Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s directions. Then
8-methoxypsoralen (8-MOP) was added to the suspen-
sion at a concentration of 0.2 mg/mL unless noted
otherwise. The cells were incubated with 8-MOP in
5% CO2 for 30 minutes at 37
C. After incubation,
the cells were exposed to UVA light (5 J/cm2) in a cali-
brated light box (Therakos, Raritan, NJ). Treated cells
were resuspended in serum-free RPMI medium and
then administered i.v. to recipient mice either 1 day
after TCR BMT (therapeutic ECP) or on the same
day as DLI after TCD BMT (prophylactic ECP).DC Culture
BM was harvested and processed as described pre-
viously [26]. Mature hematopoietic cells and their
committed precursors were depleted by magnetic
lineage cell depletion over an LS column according
to the manufacturer’s directions (Miltenyi Biotec).
The negative fraction was then resuspended in com-
plete mouse medium [26] and cultured in 5% CO2 at
37C for 8 days with interleukin (IL)-4 at 500 U/mL
and granulocyte macrophage colony-stimulating fac-
tor at 1000 U/mL. This culture system yielded
.90% myeloid DCs (CD11c1CD11b1). DCs were
activated with 4 mg/mL of anti-CD40 on day 7 and
then collected within 24 hours of activation. For exper-
iments incorporating DC vaccines, DCs were then
resuspended in serum-free RPMI media and injected
i.p. at 1  105 cells per recipient at the time of DLI.Enzyme-Linked Immunosorbent Spot Analysis
Enzyme-linked immunosorbent spot (ELISPOT)
assays were performed on recipient splenocytes using
interferon (IFN)-g mouse ELISPOT kits (R&D
Systems, Minneapolis, MN), as described previously
[26]. Synthetic peptides representing the class I domi-
nant (UTY), class I subdominant (SMCY), and class II
dominant (DBY) peptides from the male HY antigen
complex were used to stimulate IFN-g production.
Two nonspecific peptides (E7, class I, and TC, class
II) were used as control peptides to determine back-
ground, which was subtracted from the HY peptide–
stimulated wells. Each sample was run in triplicate,
with a responder:stimulator ratio of 1:1. An automated
ELISPOT plate reader (Cellular Technology, Shaker
Heights, OH) was used to count the number of spots
in each well. The total number of HY-reactive T cells
was calculated using the total splenocyte count and the
number of spots per well, as described previously [27].DC and ECP-Treated Cell Coculture Assay
DCs were generated from female B6 BM as
described earlier and placed in a 24-well plate with
complete mouse medium, IL-4, and granulocyte mac-
rophage colony-stimulating factor. On days 12, 14,
and16, media and cytokines were exchanged. In addi-
tion, titrated lipoloysaccharide (LPS) was added in
serial dilutions on day 16. ECP and irradiated cells
were added at 1  106 cells/well on day 16 to achieve
a 1:1 ratio of DCs to stimulatory cells. Each LPS
concentration plus treatment was cultured in triplicate
for each experiment. Supernatants were analyzed on
day 17 by IL-10, IL-12p70, and tumor necrosis fac-
tor-a enzyme-linked immunosorbent assays (R&D
Systems) in accordance with the manufacturer’s in-
structions. Plates were read with a Versamax micro-
plate and analyzed using SoftMAX Pro 5 reader
(Molecular Devices, Sunnyvale, CA).Statistical Analysis
Statistical tests were performed using GraphPad
Prism version 4.0c for Macintosh (GraphPad Soft-
ware, San Diego, CA). Significant differences when
comparing 2 groups were determined by the 2-tailed
Mann–Whitney test. TheKruskal–Wallis withDunn’s
multiple-comparison posttest was used to assess statis-
tical differences among 3 or more groups. A P value
\.05 was considered significant.RESULTS
ECP Leads to Uniform Apoptosis of Treated
Splenocytes in an 8-MOP Dose–Dependent
Fashion
Although it has been well established that exposure
of cells to 8-MOP and UVA light results in apoptosis,
we first wanted to establish the time course of ECP-
induced apoptosis of murine splenocytes in vitro and
then, given the heterogeneity of whole spleen, deter-
mine whether there are differences in the rate of apo-
ptosis in splenocyte subsets. After exposure of whole
murine splenocytes to 8-MOP and UVA light, we ob-
served an increase in annexin V1 (Figure 1A) as early as
10 hours after treatment and in annexin V1/7-AAD1
cells (Figure 1B) with ongoing cell death through 50
hours. The induction of apoptosis only occurred
with exposure to both 8-MOP and UVA light; there
was no effect from either treatment alone. The kinetics
of cell death did not vary much among the cell subsets
in the spleen (Figure 1C). Finally, a dose-dependent
effect on apoptosis with increasing 8-MOP concentra-
tions was noted (Figure 1D). In these experiments, the
lowest concentration at which the rate of apoptosis
plateaued was 0.2 mg/mL, consistent with previous
Figure 1. ECP-treated splenocytes induce apoptosis of lymphocytes in a time-dependent and 8-MOPdose–dependent fashion. A, Splenocytes were treated
with 8-MOP,UV light, or both (ECP), and apoptosis was determined by flow cytometric analysis of annexin Vover the course of 48 hours. B, Splenocyteswere
treatedwith 8-MOP, UV light, or both (ECP), and apoptosis was determined by flow cytometric analysis of annexin Vand 7-AADover the course of 48 hours.
C, The rate of apoptosiswas ascertained in individual splenic lymphocyte subsets andDCs by flow cytometric analysis of annexin Vand 7-AADover 48 hours.
D, Splenocytes were exposed to increasing doses of 8-MOP to determine the minimum concentration that caused maximal apoptosis.
Biol Blood Marrow Transplant 17:790-799, 2011 793Impact of ECP on GVHD and DC Vaccinesreports [6]. We used this dose for all subsequent
experiments.
Therapeutic ECPAttenuates GVHD-Associated
Weight Loss in a Strain-Independent Manner
and Expands Treg Cells
We applied ECP-treated splenocytes as an early
therapeutic intervention after TCR mHA-mismatched
allo-BMT models that cause nonlethal GVHD [26].
Intravenous injection of ECP-treated splenocytes at 24
hours after infusion of TCR BM modestly attenuated
GVHD-associated weight loss (Figure 2A). Flow
cytometric analysis demonstrated that recipients of
ECP-treated splenocytes had a slight, but statistically
significant, increase in splenic B2201 cells (Figure 2B),
as well as in CD41CD251Foxp31 Tregs in the lymph
nodes (Figure 2C), as reported previously [6]. In addi-
tion, donor strain, recipient strain, and ‘‘third-party’’
strain (different from the BMT B6 donor or C3H.SW
recipient) MHC-matched ECP-treated splenocytes
were equally effective in attenuating GVHD-associated
weight loss (Figure 2D). The impact of ECP-treated
splenocytes on GVHD was not dependent on donor or
recipient MHC class I or II antigen expression, as
demonstrated by the finding that MHC-mismatched
ECP-treated splenocytes resulted in similar attenuation
of weight loss (Figure 2E). Finally, ECP-treated spleno-
cyte infusions depleted of T cells or B cells were equally
effective in reducing GVHD-associated weight loss
(Figure S1).LPS-Activated BM-Derived Myeloid DCs
Exposed to ECP-Treated Splenocytes
Produce Increased IL-10
Apoptotic cells can regulate DC function [23,24],
and previous reports have suggested that DCs are
required for the ECP effect in a non–allo-BMT
setting [9]. Consequently, we next tested whether
ECP-treated splenocytes can modulate DCs in vitro.
Myeloid DCs (mDCs) were generated from lineage-
depleted BM cells and activated with LPS, a bacte-
ria-derived Toll-like receptor 4 agonist important in
the pathophysiology of GVHD [28,29]. Coculture of
LPS-activated mDCs with ECP-treated splenocytes
did not significantly change the expression of cell
surface markers associated with mDC activation
(Figure S2). There was also no change in tumor necro-
sis factor-a production (data not shown). However, at
low LPS concentrations, coculture of mDCs with
ECP-treated splenocytes resulted in a modest decrease
in IL-12 production (data not shown) and a more
pronounced increase in IL-10 production (Figure 3).
Interestingly, this ECP effect was lost on stimulation
with higher LPS concentrations.ECP-Modulated DCs Are Less Potent in
Inducing CD81 Immune Responses In Vivo
We next tested whether the changes in cytokine
production seen in vitro resulted in a diminished func-
tional capacity of mDCs exposed to ECP-treated
Figure 2. ECP-treated splenocytes attenuate GVHD-associated weight loss after TCR BMT, leading to an increase in B2201 cells and Tregs, and are
effective regardless of the source of ECP-treated cells. A, C3H.SW recipients received either TCD or TCR B6 BM on day 10, followed by untreated
(no ECP) or ECP-treated B6 splenocytes on day11, and were followed for weight loss (n5 7-8 mice per group). *P\.05; **P\.005. B, Flow cytometric
analysis of splenic B2201 cells performed after TCR BMT. C, Flow cytometric analysis of pooled axillary and inguinal lymph nodes for Tregs in mice given
UVA-treated splenocytes and mice given ECP-treated splenocytes after TCR BMT. *P\.05. D, C3H.SW recipients received TCR B6 BM on day 10,
followed by either untreated splenocytes (no ECP) or ECP-treated splenocytes on day 11 from the donor strain (ECP B6), the recipient
strain (ECP C3H.SW), or an MHC-matched, mHA-mismatched third party (ECP Balb.b), and followed for weight loss (n 5 7-8 mice per group).
*P\.05. E, C3H.SW recipients received TCR B6 BM on day 10, followed by untreated (no ECP) or ECP-treated MHC-mismatched (C3H.HeNCR
ECP) splenocytes on day 11 and followed for weight loss (n 5 5 mice per group). *P\.05.
Figure 3. ECP-treated splenocytes increase in vitro IL-10 production
by DCs activated with LPS. Shown are the results of enzyme-linked
immunosorbent assay for IL-10 production in supernatants of cultures
of B6 mDCs, cocultured with or without ECP-treated B6 splenocytes,
activated with increasing concentrations of LPS. *P \ .05. No IL-10
was detected at an LPS dose of 0.000 mg/mL.
794 Biol Blood Marrow Transplant 17:790-799, 2011C. M. Capitini et al.splenocytes to induce immune responses in vivo. Vac-
cination of female mice with male mDCs expressing
the mHA complex HY is known to result in expansion
of CD81 and CD41 T cells recognizing dominant
(UTY) and subdominant (SMCY) class I antigens
and dominant class II (DBY) antigens as detected by
IFN-g ELISPOT analysis [27]. Coculture of male
mDCs with female splenocytes exposed to UVA
without 8-MOP (which do not undergo apoptosis;
Figure 1) had no impact on vaccine responses
(Figure 4A). However, exposure of maleDCs to female
ECP-treated splenocytes incubated with increasing
concentrations of 8-MOP resulted in diminished
CD81T cell responses to both dominant and subdom-
inant class I antigens (Figure 4A). This effect was not
due to diminished class I expression on mDCs exposed
to ECP-treated splenocytes (Figure 4B). The CD41T
cell responses to class II antigen were not affected by
exposure of DCs to ECP-treated splenocytes.
ECP-Treated Splenocytes Attenuate Delayed
DLI-Induced GVHDWhile Preserving
Responses to a DC Vaccine
Although the effect of ECP-treated splenocytes
was seen to be consistent and statistically significant
when administered early after TCR BMT (Figure 2),the attenuation of GVHD-associated weight loss was
modest. Based on the increased IL-10 production by
mDCs that we observed in vitro, along with the finding
that higher LPS concentrations minimized this effect,
Figure 4. ECP-treated splenocytes abrogate CD81 T cell responses of female mice that did not undergo transplantation to male DC vaccination. A, B6
mice were vaccinated with female or male B6 DCs that had been exposed to ECP-treated splenocytes from varying doses of 8-MOP, after which
ELISPOT analysis was performed to quantitate IFN-g production from UTY-, SMCY-, and DBY-reactive T cells (n 5 6-22 mice per group pooled
from separate experiments). *P\ .05; **P\ .01; ***P\ .001. F, female; NS, not significant. B, Activated B6 DCs were exposed to untreated (no
ECP) or ECP-treated B6 splenocytes (ECP) and then examined by flow cytometric analysis for MHC class I and II expression.
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a prophylactic treatment for GVHD mediated by
DLI given after inflammation associated with the
preparative irradiation had diminished. To test this
hypothesis, we used a TCD BMT model with delayed
infusion of T cells on days114 and128 to control the
timing and degree of GVHD. Thymectomized BMT
recipients were used, to ensure that that all T cells
were derived from the DLI and also to mimic the
absence of thymic activity characteristic of the early
post–allo-BMT environment.
ECP-treated splenocytes were prophylactically ad-
ministered to BMT recipients as a separate injection
just before the DLI. The use of prophylactic ECP in
the setting of TCD BMT with DLI was found to
attenuate GVHD-associated weight loss from higher
DLI doses of 10  106 cells (Figure 5A) and wassubstantially more effective than ECP administered
immediately after TCR BMT (Figure 2D).
Wepreviously validated responses toHYvaccination
as a stringentmeasureof immunecompetence in thymec-
tomizedTCDhosts requiring a largeT cell inocula [30].
Thus, we next examined whether modulation of GVHD
with prophylactic ECP preserved DLI-dependent DC
vaccine responses in the absence of thymic T cell regen-
eration. Thymectomized femalemouse transplant recip-
ients received a male mDC vaccine as a separate i.p.
injection on the same day as DLI on days 114 and
128 post-BMT, and vaccine responses were measured
byELISPOTonday142.At aDLIdose of 1 106 cells,
the quantity of T cells caused a mild GVHD-associated
weight loss (Figure 5A) but was insufficient to generate
T cell responses toHY in the absence of thymic function
(Figure 5B), as we have reported previously [26].
Figure 5. ECP-treated splenocytes prevent GVHD-associated weight loss when administered before alloreactive T cell infusion, and preserve re-
sponses to a male DC vaccine. A, F1mice were given TCDB6 BM on day10, followed by B6 DLI on days114 and128 to induce GVHD. ECP treatment
was given as a separate injection just before DLI infusion as GVHD prophylaxis, and all groups were followed for weight loss (n 5 8 mice per group).
*P\.05; **P\.01. B, ELISPOTanalysis was performed on day142 to quantitate IFN-g production from UTY-, SMCY-, and DBY-reactive T cells (n5 6-8
mice per group). **P\.01; ***P\.001.
796 Biol Blood Marrow Transplant 17:790-799, 2011C. M. Capitini et al.Remarkably, at a DLI dose of 10  106 cells, which is
sufficient to causemore severeGVHD-associatedweight
loss (Figure 5A), ECP-treated splenocytes permitted
robust vaccine responses (Figure 5B), equivalent to those
seen in thymus-bearingmice that did not undergo trans-
plantation (Figure 4A).Donor BM-Derived IL-10 Contributes to the
ECP Effect on GVHD-Associated Weight Loss
Given the increased IL-10 production by mDCs
observed in the coculture experiments, we next tested
whether IL-10 is required for the therapeutic effect
of ECP-treated splenocytes in vivo. Allo-BMT
was performed in thymectomized recipients (as in
Figure 5A) using B6 IL-10–deficient or IL-10–produc-
ing wild-type BM. Alloreactive DLI from wild-type
mice was given on days 114 and 128 to induce
GVHD. Of note, by the time of DLI, CD11c1 DCs
in the spleen and lymph nodes were of donor origin
(Figure 6A), and thus the lack of IL-10 production
was restricted to hematopoietic non-T cells, including
DCs. The efficacy of ECP-treated splenocytes in
preventing GVHD induced by the delayed infusion
of IL-10–producing T cells was completely lost in re-
cipients of IL-10–deficient BM, indicating that IL-10
produced by BM-derived, non-T cells is required forthe attenuation of GVHD by ECP-treated splenocytes
(Figure 6B).DISCUSSION
Although various therapies are available to manage
steroid-refractory GVHD (albeit with poor response
rates), infection and relapse remain major complica-
tions, and strategies to preventGVHDwhile preserving
immunocompetence remain elusive. ECP represents 1
potential strategy to treatGVHDwithdemonstrated ef-
ficacy in the clinic, but the impact of ECP on immunity
is quite complex and variable in different systems. Al-
though a number of murine models have assessed the
immunomodulatory properties of ECP in non–allo-
BMT settings and correlative clinical data exist, data di-
rectly addressing themechanism of ECP in the complex
millieu of the post–allo-BMT environment are limited.
In the present study, we used a MHC-matched, mHA-
mismatched allo-BMT model to examine the impact
of ECP-treated splenocytes on GVHD-associated
weight loss using both TCR BM models and TCD
BM with delayed DLI models.
Our data confirm previous reports that ECP can
modulate GVHD in murine models and is associated
with modest increases in B2201 cells and Tregs. The
Figure 6. BM-derived IL-10 is necessary for ECP-treated splenocytes to
attenuate GVHD-associated weight loss. A, F1 recipients (CD45.11/
CD45.21) underwent transplantation with TCD B6 (CD45.21) BM on
day 10 and were sacrificed on days 13, 17, 110 and 113 for flow
cytometric analysis of CD45.21CD11c1 reconstitution in the spleen
before DLI (n 5 3 mice per time point). B, Thymectomized F1 recipients
underwent transplantation with TCD B6 wild-type or B6 IL-10-/- BM on
day 10 and then treated with DLI (10  106 cells) on days 114 and
128. ECP was given as a separate injection to indicated groups just before
DLI on days114 and128. All groupswere followed for weight loss (n5 7
mice per group).
Biol Blood Marrow Transplant 17:790-799, 2011 797Impact of ECP on GVHD and DC Vaccinesincrease in B2201 cells might reflect attenuation of
GVHD, given that a loss of B2201 cells correlating
with GVHD has been previously demonstrated in this
model [26] and other BMT models [31]. We cannot
rule out the possibility that B220 expansion contributes
to the mechanism of ECP, but B2201 cells are not re-
quired in the ECP inocula to attenuate weight loss.
The contribution of Tregs to the therapeutic effect of
ECP has been demonstrated in other allo-BMTmodels
[6] and is suggested by clinical data [32].
Here, we report for the first time that the therapeu-
tic effect of ECP is not dependent on the source of
ECP-treated cells, given that third-party ECP donor
cells are equally effective even when mismatched at
MHC class I and class II. From a clinical perspective,
the efficacy of third-party cells indicates that infusion
of ‘‘off-the-shelf’’ ECP-treated cells that do not ex-
press mHA antigens against which immune modula-
tion is desired can be considered. It is important to
note that the severity of GVHD-associated weight
loss was attenuated but not prevented, implying
that ECP-treated recipients retain some degree of
GVHD, which is consistent with clinical experience
with ECP in treating established GVHD.
Although previous reports in non–allo-BMT
models suggest that ECP preserves immune compe-
tence via antigen-specific immune suppression [9], the
impact of ECP on immune competence in allo-BMT
has not yet been established. Our data support that theinfusion of ECP-treated splenocytes acts, at least in
part, through DCs, consistent with the clinical observa-
tion of altered DC profiles in the peripheral blood of
ECP-treated patients and the impact of ECP on human
antigen-presenting cells (APCs) in vitro [12-14].
Previous reports have indicated that the efficacy of
ECP is lost with depletion of DCs from the ECP-
treated cells [9].Our results indicate that althoughdirect
modulationofDCs in theECP-treated inoculamight be
occurring in the first 48 hours, and these DCs may di-
rectly contribute to the therapeutic effect of ECP, all
cell populations, including DCs, undergo apoptosis at
the same rate, with near-complete death by 48 hours.
We also demonstrate that exposure to ECP-treated
splenocytes can indirectly attenuate the capacity for
non–ECP-treated DCs to induce immune responses in
vivo, further supporting the contention that DCs con-
tribute, at least in part, to the therapeutic effect of
ECP. Indeed, DCs are critical for the induction of
GVHD [33], and the ability of apoptotic cells to alter
the functional capacity of APCs has been described
previously [34].
Importantly, in our model, donor T cells exposed
to ECP-treated splenocytes in the recipient at the
time of infusion were less able to mediate GVHD but
responded to activated mDC vaccination expressing
nonalloantigens, suggesting that ECP-treated spleno-
cytes do not directly affect the function of nonalloreac-
tive T cells.We cannot state conclusively that immune
responses to tumor or infectious antigens, whichmight
be dependent on mDCs resident in the recipient, are
preserved as well. The ability of ECP to preserve im-
mune competence is supported by reports demonstrat-
ing that patients undergoing long-term ECP therapy
are not at greater risk for developing infections and re-
spond normally to both novel and recall antigens [35].
ECP-treated splenocytes cocultured with mDCs
modulated cytokine production, resulting in increased
IL-10. We confirmed the role of IL-10 in vivo using
IL-10–deficient BM allografts, which completely abro-
gate the therapeutic effect of ECP. Furthermore,
because theTcells in theDLI- andECP-treated spleno-
cytes were both capable of producing IL-10 in this
model, the data support the in vitro studies demonstrat-
ing that IL-10 production by BM-derived non-T cells is
required for ECP-treated splenocytes to diminish allor-
eactivity. Clinical chronic GVHD studies [36] and
tumor models [37] have shown that IL-10 can prevent
DC differentiation, making DCs poor APCs. In addi-
tion, IL-10–producingDCs have been shown to expand
Tregs in humans, potentially linkingDCmodulation by
ECP to the observed expansion of Tregs in murine
models and inhumans [7].Collectively,we favor amodel
in which infusion of ECP-treated splenocytes indirectly
modulates T cell–mediated alloreactivity via IL-10–
producing DCs not in the ECP-treated inocula, result-
ing in expansion of Tregs.
798 Biol Blood Marrow Transplant 17:790-799, 2011C. M. Capitini et al.The inability of ECP-treated splenocytes to modu-
late DC cytokine production at higher concentrations
of LPS, along with the modest impact of ECP-treated
splenocytes administered immediately after allo-BMT
at the height of inflammatory cytokines, indicates that
the effect of ECP on DCs can be overcome by a strong
activation stimulus and suggests that ECP may have en-
hanced efficacy when given before the onset of GVHD.
Compared withTCRBMT (Figure 2A, 2C, and 2D), at-
tenuationofDLI-inducedGVHD-associatedweight loss
wasmarkedly improved afterTCDBMTwhenECPwas
given before infusion of high doses of alloreactive T cells
(Figures 5A and 6B). Thus, the discrepancy of GVHD-
associated weight loss between TCR BMT and TCD
BMTmodels might reflect the fact that the GVHDme-
diated by TCR BMTmay be more severe or difficult to
treat because of the additional inflammation from the
preparative irradiation. Interestingly, ECP has been
shown to be potentially efficaciouswhen used prophylac-
tically in pilot studies in humans [38].
Taken together, our findings lead us to conclude
that the therapeutic effect mediated by the infusion
of apoptotic cells induced by ECP involvesmodulation
of mDCs with increases in B2201 cells and Tregs after
allo-BMT [6]. Our data add several key findings. First,
the source of ECP-treated cells does not have to
be recipient-derived, as is practiced clinically, but
can be from a third-party source, including MHC-
mismatched cells. ECP-treated splenocytes appear to
skew mDCs toward increased IL-10 production
in vitro, and IL-10 production by donor BM-derived
non-T cells in vivo is critical for the therapeutic effect
of ECP-treated splenocytes on GVHD-associated
weight loss. In addition, mDCs exposed to ECP-
treated splenocytes promote diminished CD81
T cell responses. Thus, our data support that the ther-
apeutic effect of ECP involves modulation of DC
cytokine production in the recipient toward a more
immunosuppressive phenotype consistent with the im-
portance of DC in the induction of GVHD. Finally,
ECP-treated splenocytes were more effective when
used as a prophylactic modality for DLI-induced
GVHD after TCD BMT, permitting CD41 and
CD81 T cell responses to an activated DC vaccine.
These observations may have implications as investi-
gators apply immunotherapeutic strategies targeting
tumor-associated or infection-associated antigens in
the setting of allo-BMT where the development of
GVHD, and current therapies for GVHD, results in
immune suppression.ACKNOWLEDGMENTS
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